دورية أكاديمية
Regulation of Tumor Dendritic Cells by Programmed Cell Death 1 Pathways.
| العنوان: | Regulation of Tumor Dendritic Cells by Programmed Cell Death 1 Pathways. |
|---|---|
| المؤلفون: | Knutson KL; Mayo Clinic, Jacksonville, FL. |
| المصدر: | Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2024 May 01; Vol. 212 (9), pp. 1397-1405. |
| نوع المنشور: | Review; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Association of Immunologists Country of Publication: United States NLM ID: 2985117R Publication Model: Print Cited Medium: Internet ISSN: 1550-6606 (Electronic) Linking ISSN: 00221767 NLM ISO Abbreviation: J Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Bethesda, MD : American Association of Immunologists Original Publication: Baltimore : Williams & Wilkins, c1950- |
| مواضيع طبية MeSH: | B7-H1 Antigen* , Neoplasms*, Humans ; Immune Checkpoint Inhibitors ; Programmed Cell Death 1 Receptor/metabolism ; Ligands ; Apoptosis ; Dendritic Cells/metabolism ; Tumor Microenvironment |
| مستخلص: | The advent of immune checkpoint blockade therapy has revolutionized cancer treatments and is partly responsible for the significant decline in cancer-related mortality observed during the last decade. Immune checkpoint inhibitors, such as anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1), have demonstrated remarkable clinical successes in a subset of cancer patients. However, a considerable proportion of patients remain refractory to immune checkpoint blockade, prompting the exploration of mechanisms of treatment resistance. Whereas much emphasis has been placed on the role of PD-L1 and PD-1 in regulating the activity of tumor-infiltrating T cells, recent studies have now shown that this immunoregulatory axis also directly regulates myeloid cell activity in the tumor microenvironment including tumor-infiltrating dendritic cells. In this review, I discuss the most recent advances in the understanding of how PD-1, PD-L1, and programmed cell death ligand 2 regulate the function of tumor-infiltrating dendritic cells, emphasizing the need for further mechanistic studies that could facilitate the development of novel combination immunotherapies for improved cancer patient benefit. (Copyright © 2024 by The American Association of Immunologists, Inc.) |
| References: | Nat Immunol. 2023 Jan;24(1):55-68. (PMID: 36581713) Front Immunol. 2019 Dec 10;10:2876. (PMID: 31921140) Blood. 2009 Jun 4;113(23):5811-8. (PMID: 19339692) Science. 2006 Jun 16;312(5780):1672-6. (PMID: 16778060) J Immunol. 2011 Jun 15;186(12):6905-13. (PMID: 21551365) Hepatology. 2022 Nov;76(5):1329-1344. (PMID: 35184329) Cancer Res. 2022 Dec 2;82(23):4373-4385. (PMID: 36130020) Nat Biomed Eng. 2021 Nov;5(11):1261-1273. (PMID: 34725504) Clin Cancer Res. 2019 Aug 1;25(15):4808-4819. (PMID: 31076547) J Exp Med. 2015 Oct 19;212(11):1947-65. (PMID: 26417005) Cell Rep. 2018 Apr 3;23(1):39-49. (PMID: 29617671) Front Oncol. 2020 Oct 28;10:538064. (PMID: 33194598) Sci Immunol. 2020 Jan 3;5(43):. (PMID: 31901074) Immunity. 2023 Jul 11;56(7):1613-1630.e5. (PMID: 37392735) J Exp Med. 2003 Jul 7;198(1):31-8. (PMID: 12847135) Ann Oncol. 2016 Jul;27(7):1362. (PMID: 27072927) J Immunol. 2003 Feb 1;170(3):1257-66. (PMID: 12538684) Immunity. 2022 Nov 8;55(11):2206-2208. (PMID: 36351377) Nat Rev Immunol. 2020 Jan;20(1):25-39. (PMID: 31570880) Cancer Cell. 2016 Aug 8;30(2):324-336. (PMID: 27424807) J Exp Med. 2001 Apr 2;193(7):839-46. (PMID: 11283156) Front Cell Dev Biol. 2022 May 25;10:883523. (PMID: 35693928) Nat Rev Immunol. 2019 Feb;19(2):89-103. (PMID: 30464294) Cancer Cell. 2020 Mar 16;37(3):289-307.e9. (PMID: 32183949) Science. 2023 Feb 17;379(6633):eabg2752. (PMID: 36795805) Sci Transl Med. 2020 Mar 11;12(534):. (PMID: 32161104) Cancer Res. 2016 Jan 15;76(2):239-50. (PMID: 26567141) J Exp Med. 2014 May 5;211(5):943-59. (PMID: 24752301) Immunity. 2022 Sep 13;55(9):1749. (PMID: 36103861) J Natl Cancer Inst. 2019 Mar 1;111(3):301-310. (PMID: 30321406) Am Soc Clin Oncol Educ Book. 2020 May;40:1-13. (PMID: 32412818) Cell Rep. 2020 Oct 13;33(2):108258. (PMID: 33053342) Commun Biol. 2021 May 14;4(1):581. (PMID: 33990697) Nat Med. 2003 May;9(5):562-7. (PMID: 12704383) Nat Struct Mol Biol. 2015 Jun;22(6):439-40. (PMID: 26036568) Cancer Cell. 2023 Mar 13;41(3):620-636.e9. (PMID: 36917954) Nature. 2023 May;617(7960):377-385. (PMID: 37138075) J Immunol. 2017 Jan 1;198(1):249-256. (PMID: 27895179) J Exp Med. 2021 Jan 4;218(1):. (PMID: 33601412) Nat Rev Clin Oncol. 2019 Jun;16(6):356-371. (PMID: 30705439) Front Immunol. 2018 Dec 07;9:2900. (PMID: 30581443) Nat Immunol. 2018 Jul;19(7):711-722. (PMID: 29925996) Cancer Res. 2017 Dec 1;77(23):6667-6678. (PMID: 28993412) Clin Cancer Res. 2017 Jun 15;23(12):3158-3167. (PMID: 28619999) Nat Immunol. 2012 Dec;13(12):1145-54. (PMID: 23160217) J Clin Invest. 2015 Sep;125(9):3384-91. (PMID: 26325035) Cancer Cell. 2018 Jan 8;33(1):60-74.e6. (PMID: 29316433) Trends Immunol. 2016 Mar;37(3):208-220. (PMID: 26858199) Nat Commun. 2022 Aug 31;13(1):5118. (PMID: 36045140) CA Cancer J Clin. 2023 Jan;73(1):17-48. (PMID: 36633525) J Immunol. 2017 Mar 15;198(6):2223-2231. (PMID: 28264998) Nat Immunol. 2020 Apr;21(4):442-454. (PMID: 32152508) Immunity. 2021 Oct 12;54(10):2338-2353.e6. (PMID: 34534439) Nature. 2020 Apr;580(7802):257-262. (PMID: 32269339) J Exp Med. 1997 Feb 3;185(3):541-50. (PMID: 9053454) Eur J Immunol. 2014 Apr;44(4):1031-8. (PMID: 24532425) Sci Adv. 2020 Sep 18;6(38):. (PMID: 32948597) Nat Immunol. 2017 Sep 19;18(10):1068-1075. (PMID: 28926543) Cancer Cell. 2014 Nov 10;26(5):623-37. (PMID: 25446896) EBioMedicine. 2022 Aug;82:104163. (PMID: 35841869) Immunity. 2016 Apr 19;44(4):924-38. (PMID: 27096321) Curr Opin Immunol. 2019 Jun;58:44-52. (PMID: 31071588) Annu Rev Pathol. 2020 Jan 24;15:493-518. (PMID: 31675482) Nat Cancer. 2020 Jul;1(7):681-691. (PMID: 35122038) Nat Immunol. 2001 Mar;2(3):261-8. (PMID: 11224527) Nat Commun. 2020 Sep 24;11(1):4835. (PMID: 32973173) Semin Immunol. 2018 Feb;35:3-11. (PMID: 29242034) N Engl J Med. 2016 Nov 3;375(18):1767-1778. (PMID: 27806234) Nature. 2015 Jul 9;523(7559):231-5. (PMID: 25970248) Immunity. 2019 May 21;50(5):1317-1334.e10. (PMID: 30979687) Cancer Res. 2014 Jun 1;74(11):2974-85. (PMID: 24728077) Oncoimmunology. 2015 Aug 31;5(3):e1085146. (PMID: 27141339) Cell Rep. 2017 Aug 22;20(8):1818-1829. (PMID: 28834746) Cancer Cell. 2023 Aug 14;41(8):1498-1515.e10. (PMID: 37451271) Nat Immunol. 2020 Apr;21(4):365-366. (PMID: 32152507) Immunity. 2018 Dec 18;49(6):1148-1161.e7. (PMID: 30552023) Clin Cancer Res. 2000 May;6(5):1755-66. (PMID: 10815894) Immunity. 2016 Apr 19;44(4):847-59. (PMID: 27037189) Cancer Res Treat. 2017 Jan;49(1):246-254. (PMID: 27456947) |
| معلومات مُعتمدة: | P50 CA116201 United States CA NCI NIH HHS; P30 CA015083 United States CA NCI NIH HHS; R01 CA276313 United States CA NCI NIH HHS; P50 CA136393 United States CA NCI NIH HHS |
| المشرفين على المادة: | 0 (B7-H1 Antigen) 0 (Immune Checkpoint Inhibitors) 0 (Programmed Cell Death 1 Receptor) 0 (Ligands) |
| تواريخ الأحداث: | Date Created: 20240415 Date Completed: 20240417 Latest Revision: 20240426 |
| رمز التحديث: | 20240426 |
| مُعرف محوري في PubMed: | PMC11027937 |
| DOI: | 10.4049/jimmunol.2300674 |
| PMID: | 38621195 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1550-6606 |
|---|---|
| DOI: | 10.4049/jimmunol.2300674 |